Cameron J Turtle - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Cameron J Turtle

Showing results (111-120 of 130) with videos related to

Pageof 13

Sort By:

Blood|April 8, 2025

A phase 1 trial of fully human BCMA CAR-T therapy for relapsed/refractory multiple myeloma with 5-year follow-upSherilyn A Tuazon, Andrew J Portuguese, Margot J Pont, et al.

Blood Advances|October 30, 2023

Timing of anti-PD-L1 antibody initiation affects efficacy/toxicity of CD19 CAR T-cell therapy for large B-cell lymphomaAlexandre V Hirayama, Erik L Kimble, Jocelyn H Wright, et al.

Oncoimmunology|July 30, 2016

CMRF-56(+) blood dendritic cells loaded with mRNA induce effective antigen-specific cytotoxic T-lymphocyte responsesPhillip D Fromm, Michael S Papadimitrious, Jennifer L Hsu, et al.

Blood|February 8, 2019

Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapyKevin A Hay, Jordan Gauthier, Alexandre V Hirayama, et al.

Transplantation and Cellular Therapy|April 9, 2023

Anakinra for Refractory Cytokine Release Syndrome or Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T Cell TherapyNicolas Gazeau, Emily C Liang, Qian Vicky Wu, et al.

Blood|September 23, 2020

Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignanciesJordan Gauthier, Evandro D Bezerra, Alexandre V Hirayama, et al.

Blood|February 21, 2019

The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cellsAlexandre V Hirayama, Jordan Gauthier, Kevin A Hay, et al.

Transplantation and Cellular Therapy|September 10, 2025

Impact of Gamma-Secretase Inhibition on Outcomes Following BCMA CAR-T Therapy in Multiple Myeloma: A Comparison of Two Phase 1 TrialsAndrew J Portuguese, Sherilyn A Tuazon, Margot J Pont, et al.

Blood Advances|July 24, 2025

Real-world outcomes of brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma: a CIBMTR analysisNausheen Ahmed, Swetha Thiruvengadam, Mehdi Hamadani, et al.

Journal for Immunotherapy of Cancer|December 18, 2020

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse eventsMarcela V Maus, Sara Alexander, Michael R Bishop, et al.

Pageof 13

Search research articles

Showing results (111-120 of 130) with videos related to

Sort By:

Pageof 13

Blood|April 8, 2025

A phase 1 trial of fully human BCMA CAR-T therapy for relapsed/refractory multiple myeloma with 5-year follow-upSherilyn A Tuazon, Andrew J Portuguese, Margot J Pont, et al.

Blood Advances|October 30, 2023

Timing of anti-PD-L1 antibody initiation affects efficacy/toxicity of CD19 CAR T-cell therapy for large B-cell lymphomaAlexandre V Hirayama, Erik L Kimble, Jocelyn H Wright, et al.

Oncoimmunology|July 30, 2016

CMRF-56(+) blood dendritic cells loaded with mRNA induce effective antigen-specific cytotoxic T-lymphocyte responsesPhillip D Fromm, Michael S Papadimitrious, Jennifer L Hsu, et al.

Blood|February 8, 2019

Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapyKevin A Hay, Jordan Gauthier, Alexandre V Hirayama, et al.

Transplantation and Cellular Therapy|April 9, 2023

Blood|September 23, 2020

Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignanciesJordan Gauthier, Evandro D Bezerra, Alexandre V Hirayama, et al.

Blood|February 21, 2019

The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cellsAlexandre V Hirayama, Jordan Gauthier, Kevin A Hay, et al.

Transplantation and Cellular Therapy|September 10, 2025

Impact of Gamma-Secretase Inhibition on Outcomes Following BCMA CAR-T Therapy in Multiple Myeloma: A Comparison of Two Phase 1 TrialsAndrew J Portuguese, Sherilyn A Tuazon, Margot J Pont, et al.

Blood Advances|July 24, 2025

Real-world outcomes of brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma: a CIBMTR analysisNausheen Ahmed, Swetha Thiruvengadam, Mehdi Hamadani, et al.

Journal for Immunotherapy of Cancer|December 18, 2020

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse eventsMarcela V Maus, Sara Alexander, Michael R Bishop, et al.

Pageof 13